Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study - PubMed
7 days ago
- #CAR T-cell therapy
- #Clinical trial
- #Marginal zone lymphoma
- Lisocabtagene maraleucel (liso-cel) demonstrated high efficacy in relapsed or refractory marginal zone lymphoma (MZL) with an overall response rate of 95%.
- The study was a phase 2, single-arm, multicohort trial involving 67 patients from 30 sites globally, with a median follow-up of 24.1 months.
- Safety profile was manageable, with grade 3 cytokine release syndrome or neurological events occurring in 4% of patients each and no grade 4-5 events.
- Subtypes of MZL included nodal (48%), splenic (27%), and extranodal-mucosa-associated lymphoid tissue (25%).
- The study supports liso-cel as a new treatment option for relapsed or refractory MZL, showing durable responses and a manageable safety profile.